Metobeta Retard (Metoprolol Tartrate)

Metoprolol tartrate selectively blocks β1‑adrenergic receptors in the heart, reducing the effects of adrenaline. This leads to a slower heart rate, decreased contractility, and lower renin release, which together lower blood pressure and myocardial oxygen demand.

The appropriate dose of Metobeta Retard is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for metoprolol tartrate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Metobeta Retard, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metobeta Retard (metoprolol tartrate) is a cardio‑selective β1‑blocker, offering a favorable profile for patients with respiratory conditions compared with non‑selective agents. Its efficacy in reducing blood pressure and protecting the heart after myocardial infarction is comparable to other agents such as atenolol, but individual response may vary.

Metobeta Retard should be stored at room temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight and sources of heat to maintain its stability.

Metobeta Retard is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber to ensure consistent absorption.

Serious risks include severe bradycardia, marked hypotension, heart block, bronchospasm in susceptible individuals, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, difficulty breathing, or a rapid change in heart rhythm.

Metobeta Retard is contraindicated in patients with known hypersensitivity to metoprolol or other beta blockers, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals experiencing cardiogenic shock. Caution is also advised for patients with uncontrolled asthma or severe peripheral vascular disease.